Glepaglutide for short bowel syndrome
Glepaglutide is a long-acting GLP-2 analog in development for the treatment of short bowel syndrome (SBS).
Many people with short bowel syndrome (SBS) are dependent on frequent intake of intravenous fluids and nutrition delivered through a central catheter.
They experience a number of serious and lifethreatening complications associated with their disease and treatment, such as shortened life expectancy as well as high risk of sepsis and other infections, blood clots, liver damage and renal impairment.
Orphan drug designation has been granted in the U.S.
Glepaglutide has an effective half-life of 50 hours. Zealand initiated the pivotal Phase 3 trial in October 2018. The trial will be a randomized, double-blind and placebo-controlled study, with both once- and twice-weekly dosing regimens. The trial is expected to enroll 129 patients at multiple sites across the United States, Europe and Canada.
My worst fear was to become what I am today: a short bowel patient
Marianne was diagnosed with cancer of the small intestine and became a short bowel patient. Today, she manages to live a life on home parenteral nutrition and works as a pastor.